145 related articles for article (PubMed ID: 35166242)
61. CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M; Flottmann S; Eckstein M; Hommerding O; Klümper N; Corvino D; Hosni S; Schmidt A; Mönig N; Schmidt D; Ellinger J; Toma M; Kristiansen G; Bald T; Alimonti A; Ritter M; Hölzel M; Alajati A
Sci Rep; 2023 Jan; 13(1):73. PubMed ID: 36593286
[TBL] [Abstract][Full Text] [Related]
62. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
Mamat S; Ikeda J; Enomoto T; Ueda Y; Rahadiani N; Tian T; Wang Y; Qiu Y; Kimura T; Aozasa K; Morii E
Oncol Rep; 2010 May; 23(5):1221-7. PubMed ID: 20372833
[TBL] [Abstract][Full Text] [Related]
63. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
[TBL] [Abstract][Full Text] [Related]
64. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
[TBL] [Abstract][Full Text] [Related]
65. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
Ikeda JI; Morii E; Kimura H; Tomita Y; Takakuwa T; Hasegawa JI; Kim YK; Miyoshi Y; Noguchi S; Nishida T; Aozasa K
J Pathol; 2006 Sep; 210(1):75-84. PubMed ID: 16823897
[TBL] [Abstract][Full Text] [Related]
66. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.
Hooper JD; Zijlstra A; Aimes RT; Liang H; Claassen GF; Tarin D; Testa JE; Quigley JP
Oncogene; 2003 Mar; 22(12):1783-94. PubMed ID: 12660814
[TBL] [Abstract][Full Text] [Related]
67. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Zhao N; Chopra S; Trepka K; Wang YH; Sakhamuri S; Hooshdaran N; Kim H; Zhou J; Lim SA; Leung KK; Egusa EA; Zhu J; Zhang L; Foye A; Sriram R; Chan E; Seo Y; Feng FY; Small EJ; Chou J; Wells JA; Aggarwal R; Evans MJ
Clin Cancer Res; 2022 Jul; 28(14):3066-3075. PubMed ID: 35604681
[TBL] [Abstract][Full Text] [Related]
68. CUB domain-containing protein 1 (CDCP1) binds transforming growth factor beta family members and increase TGF-β1 signaling pathway.
Predes D; Cruz JVR; Abreu JG; Mendes FA
Exp Cell Res; 2019 Oct; 383(1):111499. PubMed ID: 31302030
[TBL] [Abstract][Full Text] [Related]
69. Infrared spectral signatures of CDCP1-induced effects in colon carcinoma cells.
Yousef I; Bréard J; SidAhmed-Adrar N; Maâmer-Azzabi A; Marchal C; Dumas P; Le Naour F
Analyst; 2011 Dec; 136(24):5162-8. PubMed ID: 22034616
[TBL] [Abstract][Full Text] [Related]
70. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Turdo F; Bianchi F; Gasparini P; Sandri M; Sasso M; De Cecco L; Forte L; Casalini P; Aiello P; Sfondrini L; Agresti R; Carcangiu ML; Plantamura I; Sozzi G; Tagliabue E; Campiglio M
Oncotarget; 2016 Oct; 7(43):69649-69665. PubMed ID: 27626701
[TBL] [Abstract][Full Text] [Related]
71. CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.
He Y; Davies CM; Harrington BS; Hellmers L; Sheng Y; Broomfield A; McGann T; Bastick K; Zhong L; Wu A; Maresh G; McChesney S; Yau Wong K; Adams MN; Sullivan RC; Palmer JS; Burke LJ; Ewing AD; Zhang X; Margolin D; Li L; Lourie R; Matsika A; Srinivasan B; McGuckin MA; Lumley JW; Hooper JD
Oncogene; 2020 Jan; 39(1):219-233. PubMed ID: 31471585
[TBL] [Abstract][Full Text] [Related]
72. Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.
He Y; Khan T; Kryza T; Jones ML; Goh JB; Lyons NJ; Pearce LA; Lee MD; Gough M; Rogers R; Davies CM; Gilks CB; Hodgkinson T; Lourie R; Barry SC; Perrin LC; Williams CC; Puttick S; Adams TE; Munro TP; Hooper JD; Chetty N
Mol Pharm; 2021 Sep; 18(9):3464-3474. PubMed ID: 34448393
[TBL] [Abstract][Full Text] [Related]
73. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.
Perry SE; Robinson P; Melcher A; Quirke P; Bühring HJ; Cook GP; Blair GE
FEBS Lett; 2007 Mar; 581(6):1137-42. PubMed ID: 17335815
[TBL] [Abstract][Full Text] [Related]
74. Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens.
Chen Y; Harrington BS; Lau KCN; Burke LJ; He Y; Iconomou M; Palmer JS; Meade B; Lumley JW; Hooper JD
J Pharm Biomed Anal; 2017 May; 139():65-72. PubMed ID: 28279929
[TBL] [Abstract][Full Text] [Related]
75. Prognostic Significance of CDCP1 Expression in Colorectal Cancer and Effect of Its Inhibition on Invasion and Migration.
Chou CT; Li YJ; Chang CC; Yang CN; Li PS; Jeng YM; Chen ST; Kuo ML; Lin IC; Lin BR
Ann Surg Oncol; 2015 Dec; 22(13):4335-43. PubMed ID: 25820997
[TBL] [Abstract][Full Text] [Related]
76. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.
Awakura Y; Nakamura E; Takahashi T; Kotani H; Mikami Y; Kadowaki T; Myoumoto A; Akiyama H; Ito N; Kamoto T; Manabe T; Nobumasa H; Tsujimoto G; Ogawa O
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1363-9. PubMed ID: 18483744
[TBL] [Abstract][Full Text] [Related]
77. CDCP1 is a novel marker for hematopoietic stem cells.
Conze T; Lammers R; Kuci S; Scherl-Mostageer M; Schweifer N; Kanz L; Buhring HJ
Ann N Y Acad Sci; 2003 May; 996():222-6. PubMed ID: 12799299
[TBL] [Abstract][Full Text] [Related]
78. CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
Liu CL; Tsai HW; Peng SL; Chang CP; Chang YH; Huang HS
PLoS One; 2023; 18(3):e0281873. PubMed ID: 36862682
[TBL] [Abstract][Full Text] [Related]
79. Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers.
Nelson LJ; Wright HJ; Dinh NB; Nguyen KD; Razorenova OV; Heinemann FS
Am J Pathol; 2020 Feb; 190(2):484-502. PubMed ID: 31843498
[TBL] [Abstract][Full Text] [Related]
80. Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development.
Ying X; Jiang X; Zhang H; Liu B; Huang Y; Zhu X; Qi D; Yuan G; Luo J; Ji W
Mol Cancer; 2020 Dec; 19(1):169. PubMed ID: 33267838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
